Rapid Point-of-Care RNA Diagnostic for Dengue Infection

摘要 项目摘要/摘要登革病毒(DENV)是世界上最危险和最重要的病原体之一，每年有2.3亿例登革病毒感染病例，主要发生在拉丁美洲和东南亚。这些由蚊子传播的病毒会在许多热带和亚热带国家引起周期性的大流行。CrossLife Technologies的登革热诊断正在开发中，目的是在护理时及早发现登革热感染，以便患者能够得到有效治疗。在发烧期间及早和快速检测登革病毒(DENV)感染对于适当的患者管理和疾病控制至关重要。然而，目前早期检测登革热的方法涉及在实验室使用RT-PCR仪器，这在登革热流行的地区可能无法获得，而且可能太慢。CrossLife Technologies建议开发一种模板辅助快速检测(TARA)诊断方法，用于检测人类血液中的登革热病毒。Tara登革热诊断将在30分钟内在医疗点(POC)的纸条上检测到登革热，以便患者能够以低成本得到快速治疗。这项创新技术将直接从全血样本中提供无聚合酶链式反应、免仪器、低成本、一次性、快速和敏感的POC登革热诊断。

Abstract Rapid Point-of-Care RNA Diagnostic for Dengue Infection CrossLife Technologies Inc. Project Summary/Abstract Dengue viruses (DENV) are one of the most dangerous and significant pathogens in the world, and there are 230 million cases of dengue virus infections per year, mostly in Latin America and Southeast Asia. These mosquito-borne viruses cause periodic explosive epidemics in many tropical and sub-tropical countries. CrossLife technologies' dengue diagnostic is being developed to detect dengue infection early at the point-of-care so that patients can be treated effectively. Early and rapid detection of dengue virus (DENV) infection during the febrile period is crucial for proper patient management and containment of the disease. However, current methods for early detection of dengue involve the use of RT-PCR instruments in the laboratory, which may not be available in areas where dengue is endemic, and which may be too slow. CrossLife Technologies proposed to develop a Template Assisted Rapid Assay (TARA) diagnostics for detection of dengue viruses in human blood. TARA dengue diagnostic will detect dengue in 30 minutes on a paper strip at the point-of-care (POC) so that patients can be treated rapidly and at low cost. This innovative technology will provide PCR-less, instrumentation-free, low-cost, disposable, rapid and sensitive POC dengue diagnostics directly from whole blood samples.